Drug Profile
Resiniferatoxin - Grunenthal
Alternative Names: Lopain; MTX-071; RTX - Grunenthal; RTX-GRT7039Latest Information Update: 26 May 2023
Price :
$50
*
At a glance
- Originator Mestex AG
- Developer Grunenthal
- Class Acetates; Analgesics; Anti-inflammatories; Azulenes; Non-opioid analgesics; Phenols; Phenyl ethers; Small molecules
- Mechanism of Action TRPV1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Musculoskeletal pain
Most Recent Events
- 26 May 2023 Resiniferatoxin - Grunenthal receives Breakthrough Therapy status for Musculoskeletal pain in USA
- 22 May 2023 Grünenthal announces intention to submit marketing authorization application (MAA) for Musculoskeletal pain in 2025
- 31 Mar 2023 Grunenthal anticipates market authorization of resiniferatoxin for Musculoskeletal pain in Japan, European Union and USA in 2025-2026